Reaction
Polymenorrhoea reporting signals
As of the last recalculation, Polymenorrhoea appears in 3,189 FAERS reports alongside 27 co-occurring drug terms. The strongest observed disproportionality signal is ETONOGESTREL (PRR 53.1).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Etonogestrel | 347 | 53.1 | 53.5 |
| Drospirenone And Ethinyl Estradiol | 167 | 26.0 | 26.1 |
| Levonorgestrel | 545 | 21.1 | 21.2 |
| Etonogestrel And Ethinyl Estradiol | 48 | 14.3 | 14.4 |
| Standardized Senna Concentrate | 21 | 11.0 | 11.0 |
| Copper | 60 | 9.2 | 9.3 |
| Lumacaftor And Ivacaftor | 10 | 7.6 | 7.6 |
| Orlistat | 30 | 7.6 | 7.6 |
| Rabeprazole | 20 | 5.9 | 5.9 |
| Elexacaftor, Tezacaftor, And Ivacaftor | 9 | 4.7 | 4.7 |
| Progesterone | 16 | 4.6 | 4.6 |
| Fremanezumab-Vfrm | 6 | 3.4 | 3.4 |
| Icosapent Ethyl | 4 | 3.1 | 3.1 |
| Medroxyprogesterone Acetate | 22 | 2.9 | 2.9 |
| Eptinezumab-Jjmr | 4 | 2.9 | 2.9 |
| Mometasone Furoate And Formoterol Fumarate Dihydrate | 6 | 2.5 | 2.5 |
| Leuprolide Acetate | 28 | 2.4 | 2.4 |
| Galcanezumab-Gnlm | 11 | 2.3 | 2.3 |
| Voclosporin | 3 | 2.3 | 2.3 |
| Ofatumumab | 10 | 2.0 | 2.0 |
| Natalizumab | 49 | 1.8 | 1.8 |
| Dornase Alfa | 5 | 1.7 | 1.7 |
| Dimethyl Fumarate | 30 | 1.6 | 1.6 |
| Tirzepatide | 36 | 1.5 | 1.5 |
| Voxelotor | 5 | 1.5 | 1.5 |
| Erenumab-Aooe | 10 | 1.2 | 1.2 |
| Dupilumab | 61 | 0.8 | 0.8 |